ArticleCancer medicine2026
Persistent Fluorodeoxyglucose Uptake on Post-Definitive Radiotherapy PET/CT Evaluation Predicts Poor Survival in Pediatric Metastatic Ewing Sarcoma: A Single-Center Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThough PROCEDURE: Children ≤ 15 years of age with ES treated from January 2012 to December 2023 who received definitive radiotherapy to the primary and had an 18F-FDG-PET CT 3 months post completion of RT (PET-3) were analyzed retrospectively. Disease status of the soft tissue component based on PET-3 was classified as having either no residual, anatomic residual with no FDG-avidity, or FDG-avid residual.
resultsOne hundred and forty-nine patients formed the study cohort. Metastatic disease was present in 46.3% (n = 69). PET3 showed FDG-avid residual in 17.4% (n = 26), anatomic residual in 30.2% (n = 45), and no residual in 52.3% (n = 78) of patients. Five-year EFS of those with no residual, anatomic residual, and FDG-avid residual in the whole cohort were 52.8% (95% CI: 40.4%-65.2%), 45.9% (95% CI: 28.4%-63.4%), 42.6% (95% CI: 20.7%-64.6%) (p = 0.038). Among patients with FDG-avid residual disease, 5-year EFS was 22.9% (95% CI: 5.0%-45.2%) for metastatic cases compared to 75.0% (95% CI: 44.0%-100%) for localized disease (p = 0.003). A PET3 SUV
conclusionsIn patients with metastatic Ewing Sarcoma treated with definitive radiotherapy of the primary, the persistence of FDG-avid residual on post-treatment PET/CT signifies a markedly poor prognosis. In particular, a PET3 SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.